Karyopharm Therapeutics (KPTI) Short term Debt (2025 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Short term Debt came in at $21.0 million in Q4 2025, up 68.08% on a QoQ basis from $12.5 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Short term Debt (2025 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 1 years of Short term Debt data on file, last reported at $21.0 million in Q4 2025.
- Quarterly Short term Debt changed N/A year-over-year to $21.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.0 million (changed N/A YoY) and the FY2025 annual result came in at $21.0 million, changed N/A from the prior year.
- Short term Debt improved to $21.0 million in Q4 2025, from $12.5 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $21.0 million in Q4 2025 to a low of $6.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.31 Mn |
| Dec 31, 2025 | 21.01 Mn |
| Sep 30, 2025 | 12.50 Mn |
| Jun 30, 2025 | 6.25 Mn |